Protein Aggregation as a Cause for Disease

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 172)


The ability of proteins to fold into a defined and functional conformation is one of the most fundamental processes in biology. Certain conditions, however, initiate misfolding or unfolding of proteins. This leads to the loss of functional protein or it can result in a wide range of diseases. One group of diseases, which includes Alzheimer’s, Parkinson’s, Huntington’s disease, and the transmissible spongiform encephalopathies (prion diseases), involves deposition of aggregated proteins. Normally, such protein aggregates are not found in properly functioning biological systems, because a variety of mechanisms inhibit their formation. Understanding the nature of these protective mechanisms together with the understanding of factors reducing or deactivating the natural protection machinery will be crucial for developing strategies to prevent and treat these disastrous diseases.


Alzheimer Amyloid Huntington Parkinson Prion Protein deposits Quality control Toxic species 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aguzzi A, Haass C (2003) Games played by rogue proteins in prion disorders and Alzheimer’s disease. Science 302:814–818PubMedCrossRefGoogle Scholar
  2. Alberch J, Perez-Navarro E, Canals JM (2004) Neurotrophic factors in Huntington’s disease. Prog Brain Res 146:195–229PubMedCrossRefGoogle Scholar
  3. Avila J (2000) Tau aggregation into fibrillar polymers: taupathies. FEBS Lett 476:89–92PubMedCrossRefGoogle Scholar
  4. Bates G (2003) Huntingtin aggregation and toxicity in Huntington’s disease. Lancet 361:1642–1644PubMedCrossRefGoogle Scholar
  5. Beissinger M, Buchner J (1998) How chaperones fold proteins. Biol Chem. 379:245–259PubMedGoogle Scholar
  6. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552–1555PubMedCrossRefGoogle Scholar
  7. Berke SJ, Paulson HL (2003) Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev 13:253–261PubMedCrossRefGoogle Scholar
  8. Braun BC, Glickman M, Kraft R et al (1999) The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol 1:221–226PubMedCrossRefGoogle Scholar
  9. Bruce ME (2000) ‘New variant’ Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Nat Med 6:258–259PubMedCrossRefGoogle Scholar
  10. Budka H, Aguzzi A, Brown P, et al (1995) Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 5:459–466PubMedGoogle Scholar
  11. Bukau B, Horwich AL (1998) The Hsp70 and Hsp60 chaperone machines. Cell 92:351–366PubMedCrossRefGoogle Scholar
  12. Butterfield DA, Kanski J (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Aging Dev 122:945–962PubMedCrossRefGoogle Scholar
  13. Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350:134–138PubMedCrossRefGoogle Scholar
  14. Carrell RW, Lomas DA (2002) Alpha1-antitrypsin deficiency: a model for conformational diseases. N Engl J Med 346:45–53PubMedCrossRefGoogle Scholar
  15. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates fromthe innocent bystanders. Annu RevNeurosci 26:267–298Google Scholar
  16. Clark JI, Muchowski PJ (2000) Small heat-shock proteins and their potential role in human disease. Curr Opin Struct Biol 10:52–59PubMedCrossRefGoogle Scholar
  17. Collinge J (1999) Variant Creutzfeldt-Jakob disease. Lancet 354:317–323PubMedCrossRefGoogle Scholar
  18. Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24:519–550PubMedCrossRefGoogle Scholar
  19. Damas AM, Saraiva MJ (2000) Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. J Struct Biol 130:290–299PubMedCrossRefGoogle Scholar
  20. Dawson TM, Dawson VL (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111:145–151PubMedCrossRefGoogle Scholar
  21. Deyoung LR, Fink AL, Dill KA (1993) Aggregation of globular proteins. Acc Chem Res 26:614–620Google Scholar
  22. Dickson DW, Crystal HA, Bevona C et al (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285–298PubMedGoogle Scholar
  23. Dobson CM (2001) The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 356:133–145PubMedGoogle Scholar
  24. Dobson CM (2004) Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol 15:3–16PubMedCrossRefGoogle Scholar
  25. Dukan S, Farewell A, Ballestros M et al (2000) Protein oxidation in response to increased transcriptional or translational errors. Proc. Natl Acad Sci U S A 97:5746–5749PubMedCrossRefGoogle Scholar
  26. Eanes ED, Glenner GG (1968) X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16: 673–677PubMedGoogle Scholar
  27. Fink AL (1998) Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des 3:R9–R23PubMedCrossRefGoogle Scholar
  28. Forloni G, Terreni L, Bertani I et al (2002) Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms. Neurobiol Aging 23:957–976PubMedCrossRefGoogle Scholar
  29. Garcia-Mata R, Bebok Z, Sorscher EJ, Sztul ES (1999) Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 146:1239–1254PubMedCrossRefGoogle Scholar
  30. Geddes AJ, Parker KD, Atkins ED, Beighton E (1968) “Cross-beta” conformation in proteins. J Mol Biol 32:343–358PubMedCrossRefGoogle Scholar
  31. Glabe CG (2004) Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci 29:542–547PubMedCrossRefGoogle Scholar
  32. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428PubMedGoogle Scholar
  33. Glover JR, Lindquist S (1998) Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 94:73–82PubMedCrossRefGoogle Scholar
  34. Goldberg ME, Rudolph R, Jaenicke R (1991) A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced egg white lysozyme. Biochemistry 30:2790–2797PubMedGoogle Scholar
  35. Gregersen N, Bolund L, Bross P (2003) Protein misfolding, aggregation, and degradation in disease. Methods Mol Biol 232:3–16PubMedGoogle Scholar
  36. Hartl FU (1996) Molecular chaperones in cellular protein folding. Nature 381:571–579PubMedCrossRefGoogle Scholar
  37. Hartley DM, Walsh DM, Ye CP et al (1999) Protofibrillar intermediates of amyloid betaprotein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876–8884PubMedGoogle Scholar
  38. Hetz C, Soto C (2003) Protein misfolding and disease: the case of prion disorders. Cell Mol Life Sci 60: 133–143PubMedGoogle Scholar
  39. Horwich AL (2004) Chaperoned protein disaggregation-the ClpB ring uses its central channel. Cell 119: 579–581PubMedCrossRefGoogle Scholar
  40. Horwich A (2002) Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J Clin Invest 110:1221–1232PubMedCrossRefGoogle Scholar
  41. Ironside JW, Bell JE (1997) Pathology of prion diseases In: Collinge J, Palmer MS (eds) Prion diseases. Oxford University Press, Oxford, pp 57–88Google Scholar
  42. Ishimaru D, Andrade LR, Teixeira LS et al (2003) Fibrillar aggregates of the tumour suppressor p53 core domain. Biochemistry 42:9022–9027PubMedCrossRefGoogle Scholar
  43. Jaenicke R (1995) Folding and association versus misfolding and aggregation of proteins. Philos Trans R Soc Lond B Biol Sci 348:97–105PubMedGoogle Scholar
  44. Johnson RT, Gibbs CJ (1998) Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 339:1994–2004PubMedGoogle Scholar
  45. Johansson J, Weaver TE, Tjernberg LO (2004) Proteolytic generation and aggregation of peptides from transmembrane regions: lung surfactant protein C and amyloid betapeptide. Cell Mol Life Sci 61:326–335PubMedGoogle Scholar
  46. Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143:1883–1898PubMedCrossRefGoogle Scholar
  47. Kayed R, Head E, Thompson JL et al (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489PubMedCrossRefGoogle Scholar
  48. Kelly J (1998) Alternative conformation of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8:101–106PubMedCrossRefGoogle Scholar
  49. Kiefhaber T, Rudolph R, Kohler H-H, Buchner J (1991) Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Nat Biotechnol 9:825–829CrossRefGoogle Scholar
  50. Kielty CM, Shuttleworth CA (1994) Abnormal fibrillin assembly by dermal fibroblasts from two patients with Marfan syndrome. J Cell Biol 124:997–1004PubMedCrossRefGoogle Scholar
  51. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524–530PubMedCrossRefGoogle Scholar
  52. Kopito RR, Sitia R (2000) Aggresomes and Russell bodies. Symptoms of cellular indigestion? EMBO Rep 1: 225–231PubMedCrossRefGoogle Scholar
  53. Krawczak M, Chuzhanova NA, Stenson PD et al (2000) Changes in primary DNA sequence complexity influence the phenotypic consequences of mutations in human gene regulatory regions. Hum Genet 107:362–365PubMedCrossRefGoogle Scholar
  54. Kuemmerle S, Gutekunst CA, Klein AM et al (1999) Huntington aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol 46:842–849PubMedCrossRefGoogle Scholar
  55. Lange C, Rudolph R (2005) Production of recombinant proteins for therapy, diagnostics, and industrial research by in vitro folding. In: Buchner J, Kiefhaber T (eds) Protein folding handbook. Vol. 3. Wiley, Weinheim, pp 1245–1280Google Scholar
  56. Lansbury PT (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A 96:3342–3344PubMedCrossRefGoogle Scholar
  57. Layfield R, Cavey JR, Lowe J (2003) Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rep 2:343–356Google Scholar
  58. Lee S, Sowa ME, Choi JM, Tsai FT (2004) The ClpB/Hsp104 molecular chaperone-a protein disaggregating machine. J Struct Biol 146:99–105PubMedCrossRefGoogle Scholar
  59. Lomas DA, Evans DL, Finch JT, Carrell RW (1992) The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 357:605–607PubMedCrossRefGoogle Scholar
  60. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci U S A 91:12243–12247PubMedGoogle Scholar
  61. Mancini R, Fagioli C, Fra AM, Maggioni C, Sitia R (2000) Degradation of unassembled soluble Ig subunits by cytosolic proteasomes: evidence that retro translocation and degradation are coupled events. FASEB J 14: 769–778PubMedGoogle Scholar
  62. Mathew A, Morimoto RI (1998) Role of the heat-shock response in the life and death of proteins. Ann N Y Acad Sci 851:99–111PubMedGoogle Scholar
  63. Maurizi MR, Xia D (2004) Protein binding and disruption by Clp/Hsp100 chaperones. Structure 12:175–183PubMedCrossRefGoogle Scholar
  64. Mayer M, Buchner J (2004) Refolding of inclusion body proteins. Methods Mol Med 94:239–254PubMedGoogle Scholar
  65. McLean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disea. Ann Neurol 46:860–866PubMedCrossRefGoogle Scholar
  66. Merlini G, Bellotti V, Andreola A et al (2001) Protein aggregation. Clin Chem Lab Med 39:1065–1075PubMedGoogle Scholar
  67. Mogk A, Tomoyasu T, Goloubinoff P et al (1999) Identification of thermolabile Escherichia coli proteins: prevention and reversion of aggregation by DnaK and ClpB. EMBO J 18:6934–6949PubMedCrossRefGoogle Scholar
  68. Nishio I, Tanaka T, Sun ST et al (1983) Hemoglobin aggregation in single red blood cells of sickle cell anemia. Science 220:1173–1175PubMedGoogle Scholar
  69. Perutz MF (1999) Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci 24: 58–63PubMedCrossRefGoogle Scholar
  70. Pollanen MS, Dickson DW, Bergeron C (1993) Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 52:183–191PubMedGoogle Scholar
  71. Preudhomme C, Vachee A, Morschauser F et al (1994) Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase. Leuk Res 18:365–371PubMedGoogle Scholar
  72. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95:13363–13383PubMedCrossRefGoogle Scholar
  73. Prusiner SB, Scott MR (1997) Genetics of prions. Annu Rev Genet 31:139–175PubMedCrossRefGoogle Scholar
  74. Queitsch C, Hong SW, Vierling E, Lindquist S (2000) Heat shock protein 101 plays a crucial role in thermotolerance in Arabidopsis. Plant Cell 12:479–492PubMedCrossRefGoogle Scholar
  75. Rochet JC, Lansbury PT (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10: 60–68PubMedCrossRefGoogle Scholar
  76. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10 Suppl:S10–S17PubMedCrossRefGoogle Scholar
  77. Sakahira H, Breuer P, Hayer-Hartl MK, Hartl FU (2002) Molecular chaperones asmodulators of polyglutamine protein aggregation and toxicity. Proc Natl Acad Sci U S A 99[Suppl 4]:16412–16418PubMedGoogle Scholar
  78. Sanchez I, Mahlke C, Yuan J (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421:373–379PubMedGoogle Scholar
  79. Sandilands A, Hutcheson AM, Long HA et al (2002) Altered aggregation properties of mutant gamma-crystallins cause inherited cataract. EMBO J 21:6005–6014PubMedCrossRefGoogle Scholar
  80. Scheibel T (2004) Amyloid formation of a yeast prion determinant. J Mol Neurosci 23:13–22PubMedGoogle Scholar
  81. Scheibel T, Serpell L (2005) Physical methods for studies of fibre formation and structure. In: Buchner J, Kiefhaber T (eds) Protein folding handbook. Vol. 3. Wiley, Weinheim, pp 197–253Google Scholar
  82. Sharon R, Bar-Joseph I, Frosch MP et al (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37:583–595PubMedCrossRefGoogle Scholar
  83. Sherman MY, Goldberg AL (2001) Cellular defences against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15–32PubMedCrossRefGoogle Scholar
  84. Small DH, Mok SS, Bornstein JC (2001) Alzheimer’s disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2:595–598CrossRefGoogle Scholar
  85. Soti C, Csermely P (2000) Molecular chaperones and the aging process. Biogerontology 1:225–233PubMedCrossRefGoogle Scholar
  86. Speed MA, Wang DIC, King J (1996) Specific aggregation of partially folded polypeptide chains-the molecular basis of inclusion body composition. Nat Biotechnol 14:1283–1287PubMedCrossRefGoogle Scholar
  87. Stirling PC, Lundin VF, Leroux MR (2003) Getting a grip on non-native proteins. EMBO Rep 4:565–570PubMedCrossRefGoogle Scholar
  88. Stojanovic A, Hwang I, Khorana HG, Hwa J (2003) Retinitis pigmentosa rhodopsin mutations L125R and A164 V perturb critical interhelical interactions: new insights through compensatory mutations and crystal structure analysis. J Biol Chem 278:39020–39028PubMedCrossRefGoogle Scholar
  89. Sunde M, Blake C (1997) The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50:123–159PubMedGoogle Scholar
  90. Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296: 1991–1995PubMedGoogle Scholar
  91. Tennent GA, Lovat LB, Pepys MB (1995). Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92:4299–4303PubMedGoogle Scholar
  92. Teplow DB (1998) Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 5: 121–142PubMedGoogle Scholar
  93. Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedCrossRefGoogle Scholar
  94. Thakur AK, Wetzel R (2002) Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci U S A 99:17014–17019PubMedCrossRefGoogle Scholar
  95. Tooze J, Hollinshead M, Ludwig T et al (1990) In exocrine pancreas, the basolateral endocytic pathway converges with the autophagic pathway immediately after the early endosome. J Cell Biol 111:329–345PubMedCrossRefGoogle Scholar
  96. Uversky VN (2003) Protein folding revisited. A polypeptide chain at the folding-misfolding-non folding cross-roads: which way to go? Cell Mol Life Sci. 60:1852–1871PubMedCrossRefGoogle Scholar
  97. Uversky VN, Lee HJ, Li J et al (2001) Stabilisation of partially folded conformation during alpha synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 276:43495–43498PubMedGoogle Scholar
  98. Volles MJ, Lee SJ, Rochet JC et al (2001) Vesicle permeabilization by protofibrillar alphasynuclein: implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry 40:7812–7819PubMedCrossRefGoogle Scholar
  99. Walter S, Buchner J (2002) Molecular chaperones-cellular machines for protein folding. Angew Chem Int Ed Engl 41:1098–1113PubMedCrossRefGoogle Scholar
  100. Wanker EE (2000) Protein aggregation and pathogenesis of Huntington’s disease: mechanisms and correlations. Biol Chem 381:937–942PubMedCrossRefGoogle Scholar
  101. Weihofen A, Binns K, Lemberg MK et al (2002) Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296:2215–2218PubMedCrossRefGoogle Scholar
  102. Weissman AM (2001) Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2:169–178PubMedCrossRefGoogle Scholar
  103. Wigley WC, Fabunmi RP, Lee MG et al (1999) Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 145:481–490PubMedGoogle Scholar
  104. Wille H, Zhang GF, Baldwin MA et al (1996) Separation of scrapie prion infectivity from PrP amyloid polymers. J Mol Biol 259:608–621PubMedCrossRefGoogle Scholar
  105. Wu Y, Whitman I, Molmenti E et al (1994) A lag in intracellular degradation ofmutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A 91: 9014–9018PubMedGoogle Scholar
  106. Yankner BA, Caceres A, Duffy LK (1990) Nerve growth factor potentiates the neurotoxicity of beta amyloid. Proc Natl Acad Sci U S A 87:9020–9023PubMedGoogle Scholar
  107. Yao T, Cohen RE (2002) A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419:403–407PubMedCrossRefGoogle Scholar
  108. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A (2002) Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156:519–529PubMedCrossRefGoogle Scholar
  109. Zoghbi HY, Botas J (2002) Mouse and fly models of neurodegeneration. Trends Genet 18:463–471PubMedCrossRefGoogle Scholar
  110. Zwickl P, Seemuller E, Kapelari B, Baumeister W (2001) The proteasome: a supramolecular assembly designed for controlled proteolysis. Adv Protein Chem 59:187–222PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  1. 1.Department Chemie, Lehrstuhl für BiotechnologieTechnische Universität MünchenGarchingGermany

Personalised recommendations